Vericel (VCEL) Accounts Payables (2010 - 2026)
Vericel (VCEL) posted Accounts Payables of $20.6 million for Q2 2026, up 8.44% sequentially from $19.0 million in Q1 2026, and up 60.33% YoY from $12.9 million in Q2 2025.
Vericel (VCEL) Accounts Payables (2010 - 2026) Analysis & Trends
Vericel has reported Accounts Payables for 17 years, with the latest figure at $20.6 million in Q2 2026.
- Quarterly Accounts Payables rose 60.33% year-over-year to $20.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.6 million (up 60.33% YoY) and the FY2025 annual result came in at $15.8 million, down 33.63% from the prior year.
- Accounts Payables rose to $20.6 million in Q2 2026 per VCEL's latest filing, from $19.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $25.2 million in Q2 2024 and troughed at $7.8 million in Q1 2022.
- A 5-year average of $16.4 million and a median of $16.3 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 87.78% in 2022, then tumbled 49.01% in 2025.
- Over 5 years, Accounts Payables stood at $16.9 million in 2022, then surged by 32.0% to $22.3 million in 2023, then climbed by 6.72% to $23.8 million in 2024, then tumbled by 33.63% to $15.8 million in 2025, then soared by 30.24% to $20.6 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $20.6 million, $19.0 million, and $15.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 20.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.61 Mn |
| Mar 31, 2026 | 19.01 Mn |
| Dec 31, 2025 | 15.83 Mn |
| Sep 30, 2025 | 15.34 Mn |
| Jun 30, 2025 | 12.86 Mn |
| Mar 31, 2025 | 16.75 Mn |
| Dec 31, 2024 | 23.85 Mn |
| Sep 30, 2024 | 20.88 Mn |
| Jun 30, 2024 | 25.22 Mn |
| Mar 31, 2024 | 19.43 Mn |
| Dec 31, 2023 | 22.35 Mn |
| Sep 30, 2023 | 15.05 Mn |
| Jun 30, 2023 | 14.40 Mn |
| Mar 31, 2023 | 11.13 Mn |
| Dec 31, 2022 | 16.93 Mn |
| Sep 30, 2022 | 8.11 Mn |
| Jun 30, 2022 | 9.68 Mn |
| Mar 31, 2022 | 7.75 Mn |
| Dec 31, 2021 | 9.02 Mn |
| Sep 30, 2021 | 5.58 Mn |